We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

117 hedge funds and large institutions have $125M invested in Lineage Cell Therapeutics in 2017 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 40 increasing their positions, 18 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

229% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 7

122% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 18

15% more funds holding

Funds holding: 102 → 117 (+15)

3.77% more ownership

Funds ownership: 48.64% → 52.41% (+3.8%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

11% less capital invested

Capital invested by funds: $140M → $125M (-$14.9M)

Holders
117
Holders Change
+15
Holders Change %
+14.71%
% of All Funds
2.65%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
23
Increased
40
Reduced
18
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BC
Broadwood Capital
New York
+$6.72M
2
Axa
Axa
France
+$5.74M
3
Renaissance Technologies
Renaissance Technologies
New York
+$2.02M
4
Deutsche Bank
Deutsche Bank
Germany
+$1.53M
5
AG
Artal Group
Luxembourg
+$686K

Top Sellers

1
FM
Family Management
New York
-$374K
2
NFA
Nationwide Fund Advisors
Ohio
-$237K
3
MLICM
Metropolitan Life Insurance Company (MetLife)
New York
-$164K
4
DWM
Destination Wealth Management
California
-$162K
5
Group One Trading
Group One Trading
Illinois
-$62.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
QSS
76
Quantitative Systematic Strategies
Florida
$39K – – –
SC
77
Scotia Capital
Ontario, Canada
$37K – – –
ECM
78
Elgethun Capital Management
South Dakota
$32K – – –
PPA
79
Parametric Portfolio Associates
Washington
$30K +$3.2K +1,464 +10%
Citigroup
80
Citigroup
New York
$30K +$28K +12,845 +422%
RAM
81
Riggs Asset Management
Pennsylvania
$28K – – –
PP
82
Paloma Partners
Connecticut
$28K +$31.9K +14,630 New
ProShare Advisors
83
ProShare Advisors
Maryland
$28K +$32.1K +14,697 New
Parallax Volatility Advisers
84
Parallax Volatility Advisers
California
$26K +$30.1K +13,778 New
OCAM
85
Onex Canada Asset Management
Ontario, Canada
$25K – – –
UBS AM
86
UBS AM
Illinois
$24.1K +$28K +12,803 New
AB
87
Amalgamated Bank
New York
$24K +$28.4K +13,018 New
ISB
88
Iowa State Bank
Iowa
$22K – – –
IWM
89
IHT Wealth Management
Illinois
$22K +$2.29K +1,048 +13%
QPWM
90
Quadrant Private Wealth Management
Pennsylvania
$22K +$25K +11,430 New
DWA
91
Douglass Winthrop Advisors
New York
$21K – – –
UBS Group
92
UBS Group
Switzerland
$18K +$20.2K +9,243 +2,311%
CMBA
93
C.M. Bidwell & Associates
Hawaii
$18K +$20.3K +9,310 New
AIP
94
Ameritas Investment Partners
Nebraska
$13K – – –
TRCT
95
Tower Research Capital (TRC)
New York
$12K -$8.83K -4,042 -39%
Canada Life
96
Canada Life
Manitoba, Canada
$11K – – –
LTFS
97
Ladenburg Thalmann Financial Services
Florida
$11K – – –
Zurich Cantonal Bank
98
Zurich Cantonal Bank
Switzerland
$11K +$13.1K +5,982 New
AG
99
Advisor Group
Arizona
$9K +$2.5K +1,143 +31%
Macquarie Group
100
Macquarie Group
Australia
$8K +$9.48K +4,343 New
1 2 3
4
5

LCTX Hedge Fund Activity: Q4 2017 in Review

117 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q4 2017, worth a combined $125M — down 11% from $140M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new LCTX positions and 7 closed out — a net gain of 16 holders — while 40 added to existing stakes and 18 trimmed.

The largest buyer was Broadwood Capital, adding an estimated $6.72M. The largest seller was Family Management, cutting an estimated $374K.

  • 117 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q4 2017, up from 102 in Q3 2017.
  • Funds reported $125M of Lineage Cell Therapeutics stock for Q4 2017, down 11% quarter-over-quarter.
  • 23 funds opened new Lineage Cell Therapeutics positions in Q4 2017 and 7 closed out, a net change of +16 holders.
  • The largest Lineage Cell Therapeutics buyer in Q4 2017 was Broadwood Capital, an estimated $6.72M added.
  • The largest Lineage Cell Therapeutics seller in Q4 2017 was Family Management, an estimated $374K sold.

Based on aggregated 13F filings for Q4 2017.